title: Potential side-effects of endocrine treatment of long duration in prostate cancer.
abstract: Endocrine treatment of prostate cancer has been established for more than 5 decades. Focusing on immediate or short-term side effects, bilateral orchidectomy may cause psychological trauma, treatment with oral estrogens is combined with a high risk of severe cardiovascular complications, and the use of LH-RH agonists and antiandrogens as monotherapies or in combination may result in tumor flare, hot flashes, and gynecomastia. In recent years an increasing number of reports on anemia and/or osteoporosis related to endocrine treatment have been published. These side effects are regular and persistent after orchidectomy, or during treatment with LH-RH agonists, and are most often expressed with maximum androgen blockade. In contrast, anemia and/or osteoporosis are not reported with estrogen treatment or the use of nonsteroidal antiandrogens as a monotherapy regimen. Since many prostate cancer patients are treated hormonally for many years, control of Hb levels and bone mineral density before and after initiation of treatment at regular intervals is highly recommended as a standard of care.
authors.affiliation: Department of Urology, Huddinge University Hospital, Karolinska Institute, Huddinge, Sweden.
authors.forename: R
authors.initials: R
authors.lastname: Stege
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects*; D000740:Anemia / Q000139:chemically induced / Q000209:etiology; D002908:Chronic Disease; D004967:Estrogens / Q000009:adverse effects*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D009919:Orchiectomy / Q000009:adverse effects*; D010024:Osteoporosis / Q000139:chemically induced / Q000209:etiology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery*
chemical_list: D000726:Androgen Antagonists; D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone